Xilia 2 Tablet contains Glimepiride 2 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with insufficient endogenous insulin secretion. Xilia 2 is typically prescribed as an adjunct to diet and exercise to achieve optimal blood glucose levels. The medication is effective in reducing both fasting and postprandial blood glucose concentrations. It is important to monitor blood glucose regularly during therapy to avoid hypoglycemia, a potential adverse effect characterized by symptoms such as dizziness, sweating, and confusion. Dose adjustments may be necessary based on glycemic response and patient tolerance. Caution is advised in patients with hepatic or renal impairment, and it should be used with care in elderly patients due to increased risk of hypoglycemia. Xilia 2 is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to sulfonylureas. Concurrent use with other antidiabetic agents should be managed carefully to prevent additive hypoglycemic effects. Patient education on lifestyle modifications and adherence to therapy is essential for optimal treatment outcomes.